Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 114 posts found.

Eisai image

Eisai cancer drug performs in sarcoma disease

February 26, 2015
Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour

Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …

News
fda

FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill

February 16, 2015
Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid

The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review.  Lenvima …

News
Eisai image

Eisai: Fycompa decision ‘deeply regrettable’

November 11, 2014
Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel

Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …

News
Eisai image

FDA approves Eisai’s chemo side-effects drug

October 15, 2014
Research and Development, Sales and Marketing Eisai, FDA, Helsinn, akynzeo, chemotherapy, cinv

Eisai and Helsinn Healthcare’s Akynzeo (netupitant/palonosetron) has received FDA approval for the treatment of chemotherapy-induced nausea and vomiting (CINV). CINV …

News
ABPI image

ABPI and BIA establish new manufacturing partnership

September 23, 2014
Manufacturing and Production, Sales and Marketing ABPI, Actavis, AstraZeneca, BIA, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, Knowledge Transfer Network (KTN), Oxford BioMedica, Pfizer, Whitehead, bates, mmip

The ABPI and the Bioindustry Association (BIA) have jointly established a new Medicines Manufacturing Industry Partnership (MMIP) to boost medicines …

News
Priddy image

Alzheimer’s disease: pharma’s greatest challenge

April 4, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AD, Alzheimer's, Alzheimer’s, Eisai, Lunt, Pfizer, galantamine, karran, priddy

Like it or not, we are all becoming increasingly prone to a currently incurable and debilitating disease, that places an …

Feature
Biogen image

Alzheimer’s tie-up for Eisai and Biogen

March 6, 2014
Research and Development, Sales and Marketing Alzheimer's, BAN2401, Biogen IDEC, E2609, Eisai

Eisai and Biogen Idec have joined forces to look for new Alzheimer’s treatments, developing and commercialising two of the Japanese …

News
Eisai image

Eisai reorganises R&D

December 2, 2013
Research and Development, Sales and Marketing Eisai, R&D, cfu, epcs, pcu, reorganisation

Tokyo-based Eisai is to axe 130 jobs in Europe and the US as part of an attempt to shake up …

News
eisai image

Eisai signs tropical disease deal

November 12, 2013
Research and Development, Sales and Marketing Disease, Eisai, Japan, broad, ntd, tropical

Eisai has become the latest pharma firm to partner with the US-based Broad Institute to pool expertise and come up …

News
Eisai image

Eisai: reform NICE or we’ll pull out of the UK

October 21, 2013
Research and Development, Sales and Marketing Eisai, Hatfield, Hunt, NICE

Eisai has criticised NICE for being too narrow minded on assessing new drugs, and has warned it may pull its …

News
Eisai image

Eisai backs disease fund

July 12, 2013
Research and Development, Sales and Marketing Eisai, Japan, TB, partnership

A leading Japanese pharma group says that the sector should see investment in fighting diseases of the developing world as …

News
Eisai image

Eisai’s £8 million UK expansion

June 17, 2013
Manufacturing and Production Eisai

Eisai has decided to invest further into its Hertfordshire production plant in the UK towards the creation of an additional …

News

Eisai appoints chief clinical officer

April 12, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Eisai

Eisai has announced the immediate appointment of Lynn Kramer to the newly created position of chief clinical officer of Eisai …

Appointment

Pharma manufacturing news in brief

March 11, 2013
Business Services, Manufacturing and Production Actavis, DSM, Eisai, J&J, JJ, Marken, SAFC, Sagent Pharma

Actavis revises supply deal with Sagent, facility updates from Marken and SAFC, a supply deal for DSM plus another J&J …

News
Eisai image

Eisai cancer drug fails

January 14, 2013
Research and Development, Sales and Marketing Cancer, Eisai, Morphotek, farletuzumab

Eisai’s investigational oncology treatment farletuzumab has failed to reach its primary endpoint in a late-stage trial. Farletuzumab (MORAb-003) did not …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025